Superficial siderosis (SS) is a rare condition resulting from different sources of bleeding into the subpial space. The most common symptoms are: hypoacusia, ataxia, incontinence, dementia and parkinsonism. Since several neurodegenerative disorders may present with same clinical features, SS is often misdiagnosed. Here we present a case of SS misdiagnosed as idiopathic bilateral neurosensorial deafness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047722 | PMC |
| http://dx.doi.org/10.1136/bcr-2017-222639 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidental asymptomatic spinal cerebrospinal fluid leaks: single-center experience, and a presentation of seven cases.
J Neurointerv Surg
December 2024
Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA
Background: The majority of patients with spontaneous intracranial hypotension (SIH) are symptomatic. Some patients are discovered incidentally. The proportion of asymptomatic SIH has never been defined.
View Article and Find Full Text PDFInsights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer's disease.
Neural Regen Res
December 2024
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region, China.
Drug development for Alzheimer's disease Is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis. More recently, advances in the development of Lecanemab, an anti-amyloid-β monoclonal antibody, have shown positive results in reducing brain A burden and slowing cognitive decline in patients with early- stage Alzheimer's disease in the Phase III clinical trial (Clarity Alzheimer's disease). Despite these promising results, side effects such as amyloid-related imaging abnormalities (ARIA) may limit its usage.
View Article and Find Full Text PDFCognitive Impairment in Cerebral Amyloid Angiopathy: A Single-Center Prospective Cohort Study.
J Clin Med
December 2024
First Department of Psychiatry, "Aiginition" Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cognitive impairment represents a core and prodromal clinical feature of cerebral amyloid angiopathy (CAA). We sought to assess specific cognitive domains which are mainly affected among patients with CAA and to investigate probable associations with neuroimaging markers and Cerebrospinal Fluid (CSF) biomarkers. Thirty-five patients fulfilling the Boston Criteria v1.
View Article and Find Full Text PDFArticle Synopsis
- Mild cerebral small vessel disease (CSVD) markers are common but only high CSVD burden increases stroke and dementia risk, potentially identified using a multi-marker CSVD score.
- In a study of 1,154 participants aged 55 and older, those with three or more CSVD markers had a significantly higher stroke risk during an 8.6-year follow-up.
- The findings suggest that assessing CSVD burden could enhance stroke risk identification, complementing traditional risk assessments like the Framingham Stroke Risk Profile.
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
JAMA Neurol
November 2024
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Importance: Data from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.
Objectives: To describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).
Design, Setting, And Participants: Secondary data collection from the GRADUATE I/II phase 3 randomized, double-blind, placebo-controlled, 116-week parallel-group studies and their open-label extensions, including PostGraduate, with up to 210 (mean, 125) weeks of total gantenerumab treatment were conducted between 2018 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!